Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results
2015; Elsevier BV; Volume: 125; Issue: 9 Linguagem: Inglês
10.1182/blood-2014-11-612069
ISSN1528-0020
AutoresXavier Leleu, Lionel Karlin, Margaret Macro, Cyrille Hulin, Laurent Garderet, Murielle Roussel, Bertrand Arnulf, Brigitte Pegourié, Brigitte Kolb, Anne Marie Stoppa, Sabine Brechiniac, Gérald Marit, Béatrice Thielemans, Brigitte Onraed, Claire Mathiot, Anne Banos, Laurence Lacotte, Mourad Tiab, Mamoun Dib, Jean‐Gabriel Fuzibet, Marie Odile Petillon, Philippe Rodon, Marc Wetterwald, Bruno Royer, Laurence Legros, Lotfi Benboubker, Olivier Decaux, Martine Escoffre‐Barbe, Denis Caillot, Jean Paul Fermand, Philippe Moreau, Michel Attal, Hervé Avet‐Loiseau, Thierry Façon,
Tópico(s)Peptidase Inhibition and Analysis
ResumoKey Points Pom-Dex is active and well tolerated in adverse cytogenetic patients with early RRMM, particularly in those with del(17p). Pom-Dex prolonged OS in adverse cytogenetic patients with early RRMM.
Referência(s)